$9.45
-0.21-2.17%
Last update: Nov 12, 11:32 AM
DiaMedica Therapeutics Inc
DMACNASDAQ
DiaMedica Therapeutics rose 53.1% from $6.31 to $9.66, ahead of the S&P 500's +11.2%. Its worst day was Nov 5 (−16.1%), and its low came Jun 10 at $5.33.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.17 missed the $-0.16 estimate on $0.00 revenue.
−14.1% · S&P 500 −1.7%
DiaMedica Therapeutics shares rose 12.9%, while the S&P 500 rose 0.9%.
Story events cover the past 12 months · Times ET
+12.9% · S&P 500 +0.9%
DiaMedica Therapeutics shares fell 11.3%, while the S&P 500 fell 0.1%.
−11.3% · S&P 500 −0.1%
EPS of $-0.17 beat the $-0.18 estimate on $0.00 revenue.
+2.0% · S&P 500 +2.9%
EPS of $-0.19 missed the $-0.18 estimate on $0.00 revenue.
+0.2% · S&P 500 −0.3%
DiaMedica Therapeutics closed at its lowest level of the year, 15.5% below where the year started.
−1.7% · S&P 500 −1.6%
DiaMedica Therapeutics shares rose 10.2%, while the S&P 500 rose 1.6%.
+10.2% · S&P 500 +1.6%
EPS of $-0.19 beat the $-0.20 estimate on $0.00 revenue.
+3.3% · S&P 500 −0.3%
DiaMedica Therapeutics shares rose 10.2%, while the S&P 500 rose 0.3%.
+10.2% · S&P 500 +0.3%
DiaMedica Therapeutics closed at its highest level of the year, 70.7% above where the year started.
+7.7% · S&P 500 +1.7%
Where it ended: a close of $9.66 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.21).
Nothing in the past 12 months.
All DMAC dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DMAC and SPY from Benzinga historical bars. Not investment advice.
